ArticleScientific reports2026
Deoxyshikonin inhibits growth and induces apoptosis of hypertrophic scar-derived fibroblasts by downregulating FBXO expression through autophagy.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hypertrophic scar (HS) is a fibro-proliferative disorder of cutaneous wound healing, which seriously impacts the patient's quality of life. Deoxyshikonin (DSK) as a natural shikonin derivative possesses various pharmacological effects, however, whether DSK is involved in anti-fibrotic function for HS remain unclear. This study aimed to investigate the effect of DSK on HS-derived fibroblasts (HSFs) growth and reveal its possible mechanism. HSFs were isolated from human HS tissues. The viability and proliferation of HSFs under DSK treatment were evaluated by CCK-8 and EdU assays. The evaluation of the apoptotic ratio was performed using flow cytometry. The effects of DSK on FBXO2 expressions, apoptosis-associated proteins, autophagy-related proteins and the molecules involved in Mitogen-activated protein kinase (MAPK) family were evaluated by western blot and immunofluorescence staining. mRFP-GFP-LC3 overexpression adenovirus was employed to detect autophagosome formation. Co-immunoprecipitation (Co-IP) assays were performed to examined the interaction between p62 and FBXO2. DSK was found to inhibit the proliferation and induce apoptosis of HSFs. Furthermore, we found that DSK suppressed the expression of FBXO2, and FBXO2 overexpression alleviated the effect of DSK on proliferation and apoptosis of HSFs. DSK possessed capability to induce autophagy by which elevating FBXO2 degradation by p62 interaction. Inhibiting autophagy using Atg5 shRNA increased FBXO2 expression and decreased apoptotic protein expression under DSK stimulation. Mechanistically, DSK-induced autophagy mediated the down-regulation of FBXO2 by activating extracellular regulated kinase 1/2 (ERK1/2) signaling. In conclusion, our finding demonstrated that DSK inhibited proliferation and induced apoptosis of HSFs by autophagy-mediated degradation of FBXO2 via activating ERK1/2 signaling. DSK emerges as a promising strategy to enhance outcome of hypertrophic scar.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.